Citadel Advisors’s Metagenomi Therapeutics MGX Stock Holding History
Bought
Maintained
Sold
Other funds holding MGX
Citadel Advisors's MGX Position: Q3 2026 in Review
Citadel Advisors increased its Metagenomi Therapeutics (MGX) stake by 176% in Q3 2026, buying an estimated $37.8K and bringing the position to 49,266 shares worth $52.2K. The position accounts for ﹤0.01% of the portfolio, ranked #13346.
Citadel Advisors first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $7.52M in Q1 2024. 44 funds tracked by Wall St. Rank hold MGX as of Q3 2026.
- Citadel Advisors held 49,266 shares of Metagenomi Therapeutics worth $52.2K as of Q3 2026.
- Citadel Advisors bought 31,415 Metagenomi Therapeutics shares in Q3 2026, an estimated $37.8K.
- Metagenomi Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #13346 holding.
- Citadel Advisors first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
- Citadel Advisors's Metagenomi Therapeutics position peaked at $7.52M in Q1 2024.
- 44 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.